Pub Date : 2022-11-03DOI: 10.32756/0869-5490-2022-4-18-27
P. Novikov, S. Moiseev
The isolation of glucocorticoids (GC) was a tremendous achievement in the history of medicine and had a clinical impact similar to that of the discovery of insulin or antibiotics. However, with the expansion of their use, multiple side effects have become evident even patients treated with low doses. GC remain one of the main agents in the treatment of systemic lupus erythematosus (SLE). The studies of genomic and nongenomic effects of GC justified their use in lower starting doses (e.g. 30 to 40 mg daily) even in patiens with lupus nephritis. Methylprednisolone pulses and early initiation of hydroxychloroquine and immunosuppressive agents may allow more rapid tapering and discontinuation of GC in SLE patients. Development of novel steroid-sparing agents, e.g. anifrolumab, a monoclonal antibody to interferon I receptor, or voclosporin, an oral calcineurin inhibitor, may result in further improvement in the efficacy and safety of treatment.
{"title":"Glucocorticoids in systemic lupus erythematosus: future of steroid-sparing therapy","authors":"P. Novikov, S. Moiseev","doi":"10.32756/0869-5490-2022-4-18-27","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-4-18-27","url":null,"abstract":"The isolation of glucocorticoids (GC) was a tremendous achievement in the history of medicine and had a clinical impact similar to that of the discovery of insulin or antibiotics. However, with the expansion of their use, multiple side effects have become evident even patients treated with low doses. GC remain one of the main agents in the treatment of systemic lupus erythematosus (SLE). The studies of genomic and nongenomic effects of GC justified their use in lower starting doses (e.g. 30 to 40 mg daily) even in patiens with lupus nephritis. Methylprednisolone pulses and early initiation of hydroxychloroquine and immunosuppressive agents may allow more rapid tapering and discontinuation of GC in SLE patients. Development of novel steroid-sparing agents, e.g. anifrolumab, a monoclonal antibody to interferon I receptor, or voclosporin, an oral calcineurin inhibitor, may result in further improvement in the efficacy and safety of treatment.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87990625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-03DOI: 10.32756/0869-5490-2022-4-28-34
A. Moiseev, N. Bulanov, E. Tao, E. Mershina, V. Sholomova, S. Moiseev
To evaluate the efficacy and safety of long-term enzyme replacement therapy (ERT) in the Russian population of patients with Fabry disease (FD).
目的:评价长期酶替代疗法(ERT)在俄罗斯法布里病(FD)患者中的疗效和安全性。
{"title":"Efficacy and safety of long-term enzyme replacement therapy with agalsidase alfa or agalsidase beta in adult patients with Fabry disease","authors":"A. Moiseev, N. Bulanov, E. Tao, E. Mershina, V. Sholomova, S. Moiseev","doi":"10.32756/0869-5490-2022-4-28-34","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-4-28-34","url":null,"abstract":"To evaluate the efficacy and safety of long-term enzyme replacement therapy (ERT) in the Russian population of patients with Fabry disease (FD).","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79087106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-03DOI: 10.32756/0869-5490-2022-4-48-50
I. N. Schendrigin, S. Piskov
The first line treatments for acute gouty arthritis are nonsteroidal anti-inflammatory drugs (NSAID), corticosteroids, and colchicine. However, these agents are ineffective or contraindicated in a proportion of patients. Interleukin (IL)-1 is a key mediator in the pathogenesis of acute gouty arthritis. Recently, three IL-1-targeted agents have been developed, including anakinra, the IL-1 receptor antagonist. The authors present two patients with a flare of refractory tophaceous gout who were treated with anakinra.
{"title":"Anti-inflammatory effect of anakinra, an interleukin-1 receptor inhibitor, in patients with refractory tophaceous gout","authors":"I. N. Schendrigin, S. Piskov","doi":"10.32756/0869-5490-2022-4-48-50","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-4-48-50","url":null,"abstract":"The first line treatments for acute gouty arthritis are nonsteroidal anti-inflammatory drugs (NSAID), corticosteroids, and colchicine. However, these agents are ineffective or contraindicated in a proportion of patients. Interleukin (IL)-1 is a key mediator in the pathogenesis of acute gouty arthritis. Recently, three IL-1-targeted agents have been developed, including anakinra, the IL-1 receptor antagonist. The authors present two patients with a flare of refractory tophaceous gout who were treated with anakinra.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80855410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-03DOI: 10.32756/0869-5490-2022-4-7-17
S. Moiseev, N. Bulanov
Systemic autoimmune and autoinflammatory disease are associated with all types of diffuse kidney disease, that is, glomerulonephritis (including rapidly progressive), thrombotic microangiopathy, tubulointerstitial nephritis, and AA-amyloidosis. However, the occurrence and types of nephropathies differ significantly in patients with various systemic immunemediated inflammatory diseases. For example, glomerulonephritis is one of the leading manifestation of systemic lupus erythematosus and small-vessels vasculitis, thrombotic angiopathy occurs frequently in patients with both primary and secondary antiphosholipid syndrome, tubulointerstitial nephritis is frequently found in patients with Sjogren syndrome and IgG4-associated disease, whereas AA-amyloidosis can complicate rheumatoid arthritis, ankylosing spondilytis, psoriatic arthritis, familial Meditarranean fever, and certain other monogenic autoinflammatory diseases. Over last decades, renal survival in patients with autoimmune and autoinflammatory diseases improved significantly due to earlier diagnosis and development of effective immunosuppressive and anti-inflammatory treatments. However, a proportion of patients still present with progressive impairment of kidney function that can be unrelated to activity of underlying diseases.
{"title":"Autoimmunity, autoinflammation and kidney","authors":"S. Moiseev, N. Bulanov","doi":"10.32756/0869-5490-2022-4-7-17","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-4-7-17","url":null,"abstract":"Systemic autoimmune and autoinflammatory disease are associated with all types of diffuse kidney disease, that is, glomerulonephritis (including rapidly progressive), thrombotic microangiopathy, tubulointerstitial nephritis, and AA-amyloidosis. However, the occurrence and types of nephropathies differ significantly in patients with various systemic immunemediated inflammatory diseases. For example, glomerulonephritis is one of the leading manifestation of systemic lupus erythematosus and small-vessels vasculitis, thrombotic angiopathy occurs frequently in patients with both primary and secondary antiphosholipid syndrome, tubulointerstitial nephritis is frequently found in patients with Sjogren syndrome and IgG4-associated disease, whereas AA-amyloidosis can complicate rheumatoid arthritis, ankylosing spondilytis, psoriatic arthritis, familial Meditarranean fever, and certain other monogenic autoinflammatory diseases. Over last decades, renal survival in patients with autoimmune and autoinflammatory diseases improved significantly due to earlier diagnosis and development of effective immunosuppressive and anti-inflammatory treatments. However, a proportion of patients still present with progressive impairment of kidney function that can be unrelated to activity of underlying diseases.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89270238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-03DOI: 10.32756/0869-5490-2022-4-40-47
P. Novikov, E. Kuznetsova, N. Nosova, T. Shevtsova, M. Litvinova, V. Logina, S. Moiseev
Levilimab is a monoclonal antibody targeting interleukin-6 receptors and having a potent anti-inflammatory activity. Efficacy and safety of levilimab for treatment of rheumatoid arthritis were established in multicenter, double blind, placebo-controlled clinical trials AURORA and SOLAR. The authors present two patients with rheumatoid arthritis who were treated successfully with levilimab and discuss various issues of its use in clinical practice.
{"title":"Practical issues in the use of levilimab, a novel interleukin-6 receptor inhibitor, in patients with rheumatoid arthritis","authors":"P. Novikov, E. Kuznetsova, N. Nosova, T. Shevtsova, M. Litvinova, V. Logina, S. Moiseev","doi":"10.32756/0869-5490-2022-4-40-47","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-4-40-47","url":null,"abstract":"Levilimab is a monoclonal antibody targeting interleukin-6 receptors and having a potent anti-inflammatory activity. Efficacy and safety of levilimab for treatment of rheumatoid arthritis were established in multicenter, double blind, placebo-controlled clinical trials AURORA and SOLAR. The authors present two patients with rheumatoid arthritis who were treated successfully with levilimab and discuss various issues of its use in clinical practice.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78906346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-03DOI: 10.32756/0869-5490-2022-4-51-60
N. V. Bunchuk
An article reviews occurence, mechanism and treatment of drug induced reactions that resemble certain idiopathic rheumatic diseases and syndromes or are indistinguishable from them, that is, drug-induced lupus erythematosus, hyperuricemia and gout, osteopathy, statin-induced skeletal muscle damage, fluoroquinolone-induced tendinopathy, and autoimmune and inflammatory syndromes induced by checkpoint inhibitors.
{"title":"Drug-induced rheumatological syndromes","authors":"N. V. Bunchuk","doi":"10.32756/0869-5490-2022-4-51-60","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-4-51-60","url":null,"abstract":"An article reviews occurence, mechanism and treatment of drug induced reactions that resemble certain idiopathic rheumatic diseases and syndromes or are indistinguishable from them, that is, drug-induced lupus erythematosus, hyperuricemia and gout, osteopathy, statin-induced skeletal muscle damage, fluoroquinolone-induced tendinopathy, and autoimmune and inflammatory syndromes induced by checkpoint inhibitors.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80512417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-03DOI: 10.32756/0869-5490-2022-4-61-64
L. V. Klimov
Musculoskeletal pain is one of the main manifestations of joint and spine diseases. Chronic pain poses an enormous burden for patients, society and health care system. Patient with musculoskeletal pain requires multimodal therapy. Risk factors for chronic pain should be identified using biopsycho social model. Review article presents approaches to treatment of musculoskeletal pain.
{"title":"Musculoskeletal pain: diagnostic issues and treatment","authors":"L. V. Klimov","doi":"10.32756/0869-5490-2022-4-61-64","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-4-61-64","url":null,"abstract":"Musculoskeletal pain is one of the main manifestations of joint and spine diseases. Chronic pain poses an enormous burden for patients, society and health care system. Patient with musculoskeletal pain requires multimodal therapy. Risk factors for chronic pain should be identified using biopsycho social model. Review article presents approaches to treatment of musculoskeletal pain.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"68 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84806973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-03DOI: 10.32756/0869-5490-2022-4-35-39
O. Arisheva, A. Ivanov, I. Garmash, L. Goreva, M. Markova, S. Avdoshina, N. N. Terebilina, S. Pirozhkov, V. Baronets, D. I. Peregud, Z. Kobalava
To study the interrelations between the rs4073 polymorphism of the IL-8 gene, IL-8 serum levels and severity of alcoholic hepatitis (AH).
目的:探讨IL-8基因rs4073多态性、血清IL-8水平与酒精性肝炎(AH)严重程度的关系。
{"title":"Interaction between rs4073 IL-8 gene polymorphism, serum IL-8 and development of alcoholic hepatitis","authors":"O. Arisheva, A. Ivanov, I. Garmash, L. Goreva, M. Markova, S. Avdoshina, N. N. Terebilina, S. Pirozhkov, V. Baronets, D. I. Peregud, Z. Kobalava","doi":"10.32756/0869-5490-2022-4-35-39","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-4-35-39","url":null,"abstract":"To study the interrelations between the rs4073 polymorphism of the IL-8 gene, IL-8 serum levels and severity of alcoholic hepatitis (AH).","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78225264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-12DOI: 10.32756/0869-5490-2022-3-67-73
K. Karnoukh, E. Shikh, N. Lazareva
To assess the changes in the drug resistance index (DRI), a composite measure that combines the level of resistance of individual pathogens with the extent of antimicrobial drugs consumption in a multidisciplinary hospital, after implementation of the antimicrobial stewardship program (AMSP) and during COVID-19 pandemic.
{"title":"The drug resistance index as an indicator for the impact of antimicrobial stewardship program implementation","authors":"K. Karnoukh, E. Shikh, N. Lazareva","doi":"10.32756/0869-5490-2022-3-67-73","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-3-67-73","url":null,"abstract":"To assess the changes in the drug resistance index (DRI), a composite measure that combines the level of resistance of individual pathogens with the extent of antimicrobial drugs consumption in a multidisciplinary hospital, after implementation of the antimicrobial stewardship program (AMSP) and during COVID-19 pandemic.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"612 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77355892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-12DOI: 10.32756/0869-5490-2022-3-4-8
I. N. Samartsev, S. A. Zhivolupov
The high prevalence of stroke worldwide requires a revision of the modern doctrine of the management of patients with cerebrovascular disease. It is obvious that only aggressive modification of risk factors for vascular pathology does not guarantee the prevention of acute cerebrovascular accident, which is an intermediate or final stage of cerebrovascular disease. In this regard, the use of neuroprotectors, including vinpocetine, can increase the tolerance of brain tissue to hypoxia. Vinpocetine, a derivative of the alkaloid vincamine, inhibiting phosphodiesterase and voltage-dependent Na+- channels is widely used in many countries for the treatment of cerebrovascular diseases, including chronic cerebral ischemia. Recent studies have identified a number of new therapeutic effects of vinpocetine, including stimulation of neuroplasticity via brain-derived neurotrophic factor and inhibition of neuroinflammation. The latter mechanism is mediated by the effect on NF-kB that suppresses the expression of NF-kBdependent pro-inflammatory molecules and prevents the formation of NLRP3 inflammasome. New data allow to reconsider the place of vinpocetine in the prevention and treatment of cerebrovascular disorders, and to recommend its use in a wide range of patients with chronic cerebral ischemia.
{"title":"New prospects for drug treatment of chronic cerebral ischemia from the standpoint of neuroinflammation","authors":"I. N. Samartsev, S. A. Zhivolupov","doi":"10.32756/0869-5490-2022-3-4-8","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-3-4-8","url":null,"abstract":"The high prevalence of stroke worldwide requires a revision of the modern doctrine of the management of patients with cerebrovascular disease. It is obvious that only aggressive modification of risk factors for vascular pathology does not guarantee the prevention of acute cerebrovascular accident, which is an intermediate or final stage of cerebrovascular disease. In this regard, the use of neuroprotectors, including vinpocetine, can increase the tolerance of brain tissue to hypoxia. Vinpocetine, a derivative of the alkaloid vincamine, inhibiting phosphodiesterase and voltage-dependent Na+- channels is widely used in many countries for the treatment of cerebrovascular diseases, including chronic cerebral ischemia. Recent studies have identified a number of new therapeutic effects of vinpocetine, including stimulation of neuroplasticity via brain-derived neurotrophic factor and inhibition of neuroinflammation. The latter mechanism is mediated by the effect on NF-kB that suppresses the expression of NF-kBdependent pro-inflammatory molecules and prevents the formation of NLRP3 inflammasome. New data allow to reconsider the place of vinpocetine in the prevention and treatment of cerebrovascular disorders, and to recommend its use in a wide range of patients with chronic cerebral ischemia.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91540088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：